INOVIO has clinically demonstrated that DNA medicines can be delivered directly into cells in the body via a proprietary smart device to produce a safe and tolerable immune response robust enough to potentially treat or prevent diseases related to human papillomavirus (HPV), cancers, and infectious diseases.
With more than 2,000 patients receiving INOVIO DNA medicines in more than 7,000 applications across a range of clinical trials, INOVIO’s DNA medicines have a strong track record of activating safe, robust, and fully functional T cell and antibody responses against targeted pathogens and cancers.
FIRST DNA medicine in Phase 3 clinical trials (VGX-3100 for precancerous cervical dysplasia caused by high-risk HPV 16/18)
FIRST to show destruction/clearance of high-risk HPV 16/18 in Phase 2b trial (VGX-3100)
FIRST DNA medicine as a potential non-surgical treatment for rare, debilitating, and potentially life-threatening recurrent respiratory papillomatosis (RRP) caused by HPV 6/11 (INO-3107)
FIRST to show complete remission in Phase 1 with two PD-1s for head and neck cancer caused by high-risk HPV 16/18 (MEDI0457, licensed out to AstraZeneca)
FIRST DNA medicine to show potential for efficacy in glioblastoma multiforme (GBM), the most deadly brain cancer and one of the most aggressive cancers overall
FIRST DNA medicine to show a break in tolerance against self-antigens such as WT-1 (Wilms Tumor-1), a protein important in attacking cancer cells
FIRST DNA medicine to create anti-prostate cancer-specific T cells
© Copyright 2020 INOVIO Pharmaceuticals. All rights reserved.